115 related articles for article (PubMed ID: 36947006)
1. Preclinical Evidence that Arctigenin Effectively and Selectively Targets Clear Cell Renal Cell Carcinoma Via Suppressing EGFR and RhoA.
Liu D; Zhou G; Xu M
Nutr Cancer; 2023; 75(5):1373-1381. PubMed ID: 36947006
[TBL] [Abstract][Full Text] [Related]
2. MFN2 suppresses clear cell renal cell carcinoma progression by modulating mitochondria-dependent dephosphorylation of EGFR.
Luo L; Wei D; Pan Y; Wang QX; Feng JX; Yu B; Kang T; Luo J; Yang J; Gao S
Cancer Commun (Lond); 2023 Jul; 43(7):808-833. PubMed ID: 37378422
[TBL] [Abstract][Full Text] [Related]
3. Preclinical activity of cobimetinib alone or in combination with chemotherapy and targeted therapies in renal cell carcinoma.
Zhang L; Xie D; Lei Y; Na A; Zhu L
Future Oncol; 2021 Aug; 17(23):3051-3060. PubMed ID: 33906367
[No Abstract] [Full Text] [Related]
4. ADAM12 promotes clear cell renal cell carcinoma progression and triggers EMT via EGFR/ERK signaling pathway.
Xu J; Wang Y; Jiang J; Yin C; Shi B
J Transl Med; 2023 Jan; 21(1):56. PubMed ID: 36717944
[TBL] [Abstract][Full Text] [Related]
5. RIN1 promotes renal cell carcinoma malignancy by activating EGFR signaling through Rab25.
Feng ZH; Fang Y; Zhao LY; Lu J; Wang YQ; Chen ZH; Huang Y; Wei JH; Liang YP; Cen JJ; Pan YH; Liao B; Chen W; Luo JH
Cancer Sci; 2017 Aug; 108(8):1620-1627. PubMed ID: 28612496
[TBL] [Abstract][Full Text] [Related]
6. LINC00037 Inhibits Proliferation of Renal Cell Carcinoma Cells in an Epidermal Growth Factor Receptor-Dependent Way.
Gong X; Du X; Xu Y; Zheng W
Cell Physiol Biochem; 2018; 45(2):523-536. PubMed ID: 29393141
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
[TBL] [Abstract][Full Text] [Related]
8. RP11-367G18.1 V2 enhances clear cell renal cell carcinoma progression via induction of epithelial-mesenchymal transition.
Shao IH; Peng PH; Wu HH; Chen JL; Lai JC; Chang JS; Wu HT; Wu KJ; Pang ST; Hsu KW
Cancer Med; 2023 Apr; 12(8):9788-9801. PubMed ID: 36847128
[TBL] [Abstract][Full Text] [Related]
9. miRNA‑205‑5p functions as a tumor suppressor by negatively regulating VEGFA and PI3K/Akt/mTOR signaling in renal carcinoma cells.
Huang J; Wang X; Wen G; Ren Y
Oncol Rep; 2019 Nov; 42(5):1677-1688. PubMed ID: 31545453
[TBL] [Abstract][Full Text] [Related]
10. Peglated-H1/pHGFK1 nanoparticles enhance anti-tumor effects of sorafenib by inhibition of drug-induced autophagy and stemness in renal cell carcinoma.
Gao X; Jiang P; Zhang Q; Liu Q; Jiang S; Liu L; Guo M; Cheng Q; Zheng J; Yao H
J Exp Clin Cancer Res; 2019 Aug; 38(1):362. PubMed ID: 31426831
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of immunohistochemical staining for myoferlin in clear cell renal cell carcinoma and its association with epidermal growth factor receptor expression.
Jung M; Lee C; Park JH; Moon KC
Urol Oncol; 2019 Nov; 37(11):812.e9-812.e16. PubMed ID: 31421995
[TBL] [Abstract][Full Text] [Related]
12. MiR-182-5p inhibits the tumorigenesis of clear cell renal cell carcinoma by repressing UBE2T.
Wu Y; Zhang C; Peng D; He S; Huang C; Qian J; Zhu W; Feng N; Gong Y; Li X; Zhou L
Hum Cell; 2022 Mar; 35(2):542-556. PubMed ID: 35129808
[TBL] [Abstract][Full Text] [Related]
13. PTPN3 Inhibits the Growth and Metastasis of Clear Cell Renal Cell Carcinoma via Inhibition of PI3K/AKT Signaling.
Peng XS; Yang JP; Qiang YY; Sun R; Cao Y; Zheng LS; Peng LX; Lang YH; Mei Y; Li CZ; Meng DF; Liu ZJ; Wang MD; Zhou FJ; Huang BJ; Qian CN
Mol Cancer Res; 2020 Jun; 18(6):903-912. PubMed ID: 32169891
[TBL] [Abstract][Full Text] [Related]
14. Rac Signaling Drives Clear Cell Renal Carcinoma Tumor Growth by Priming the Tumor Microenvironment for an Angiogenic Switch.
Goka ET; Chaturvedi P; Lopez DTM; Lippman ME
Mol Cancer Ther; 2020 Jul; 19(7):1462-1473. PubMed ID: 32371578
[TBL] [Abstract][Full Text] [Related]
15. FOXK2 suppresses the malignant phenotype and induces apoptosis through inhibition of EGFR in clear-cell renal cell carcinoma.
Zhang F; Ma X; Li H; Zhang Y; Li X; Chen L; Guo G; Gao Y; Gu L; Xie Y; Duan J; Zhang X
Int J Cancer; 2018 Jun; 142(12):2543-2557. PubMed ID: 29368368
[TBL] [Abstract][Full Text] [Related]
16. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
17. Ubiquitin specific peptidase 19 is a prognostic biomarker and affect the proliferation and migration of clear cell renal cell carcinoma.
Hu W; Su Y; Fei X; Wang X; Zhang G; Su C; Du T; Yang T; Wang G; Tang Z; Zhang J
Oncol Rep; 2020 Jun; 43(6):1964-1974. PubMed ID: 32236633
[TBL] [Abstract][Full Text] [Related]
18. Activation and function of receptor tyrosine kinases in human clear cell renal cell carcinomas.
Zhang Q; Liu JH; Liu JL; Qi CT; Yan L; Chen Y; Yu Q
BMC Cancer; 2019 Nov; 19(1):1044. PubMed ID: 31690270
[TBL] [Abstract][Full Text] [Related]
19. Fucoidan inhibits EGFR redistribution and potentiates sorafenib to overcome sorafenib-resistant hepatocellular carcinoma.
Luo J; Li L; Zhu Z; Chang B; Deng F; Wang D; Lu X; Zuo D; Chen Q; Zhou J
Biomed Pharmacother; 2022 Oct; 154():113602. PubMed ID: 36029544
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
